期刊
JOURNAL OF CLINICAL DENSITOMETRY
卷 7, 期 3, 页码 255-261出版社
ELSEVIER SCIENCE INC
DOI: 10.1385/JCD:7:3:255
关键词
bone mineral density; vertebral fractures; risedronate; surrogate measure; osteoporosis; antiresorptive therapy
Low bone mineral density (BMD) is correlated with increased fracture risk. Whether greater BMD increases induced by osteoporosis drugs are related to greater decreases in fracture risk is controversial. We analyzed the relationship between BMD change and fracture risk in postmenopausal osteoporotic women receiving antiresorptive treatment. The analysis combined data from three pivotal risedronate fracture end-point trials. Women received risedronate (n = 2047) or placebo (n = 1177) daily for up to 3 yr. The BMD and vertebral radiographs were assessed periodically during 3 yr. The estimated risk of new vertebral fracture was compared between patients whose BMD increased and those whose BMD decreased. Risedronate-treated patients whose BMD decreased were at a significantly greater risk (p = 0.003) of sustaining a vertebral fracture than patients whose BMD increased. The fracture risk was similar (about 10%) in resedronate-treated patients whose increases in BMD were < 5% (the median change from baseline) and in those whose increases were greater than or equal to 5% (p = 0.453). The changes in lumbar spine BMD explained only 18% (95% confidence interval [Cl], 10%, 26%; p < 0.001) of risedronate's vertebral fracture efficacy. Although patients showing an increase in BMD had a lower fracture risk than patients showing a decrease in BMD, greater increases in BMD did not necessarily predict greater decreases in fracture risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据